Skip to main content

Pancreatic cancer: An update

Current Oncology Reports volume 9, pages 170–176 (2007)Cite this article

Abstract

Pancreatic cancer is refractory to most chemotherapy. For many years, the only active agent for this disease was gemcitabine, which has very modest activity. Two new regimens, gemcitabine plus erlotinib and gemcitabine plus capecitabine, have recently demonstrated statistically significant survival improvements compared with single-agent gemcitabine. Several key negative studies have also been reported recently. This review discusses recent trials that have changed the standard of care for patients with advanced pancreatic cancer.

This is a preview of subscription content, access via your institution.

Access options

Buy single article

Instant access to the full article PDF.

43,34 €

Price includes VAT (Finland)
Tax calculation will be finalised during checkout.

References and Recommended Reading

  1. Jemal A, Siegel R, Ward E, et al.: Cancer statistics, 2006. CA J Clin 2006, 56:106–130.

    Article  Google Scholar 

  2. Gloeckler Ries LA, Reichman ME, Lewis DR, et al.: Cancer survival and incidence from the Surveillance, Epidemiology, and End Results (SEER) program. Oncologist 2003, 8:541–552.

    PubMed  Article  Google Scholar 

  3. Burris HA III, Moore MJ, Andersen J, et al.: Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 1997, 15:2403–2413.

    PubMed  CAS  Google Scholar 

  4. Friberg G, Kindler HL: Chemotherapy for advanced pancreatic cancer: past, present, and future. Curr Oncol Rep 2005, 7:186–195.

    PubMed  Article  CAS  Google Scholar 

  5. Moore MJ, Goldstein D, Hamm J, et al.: Erlotinib plus gemcitabine compared to gemcitabine alone in patients with advanced pancreatic cancer. A phase III trial of the National Cancer Institute of Canada Clinical Trials Group [NCIC-CTG] [abstract]. Proc ASCO 2005, 23(16S):1s.

    Google Scholar 

  6. Cunningham D, Chau I, Stocken C, et al.: Phase III randomised comparison of gemcitabine (GEM) versus gemcitabine plus capecitabine (GEM-CAP) in patients with advanced pancreatic cancer. Eur J Cancer 2005, 3(Suppl):S4.

    Google Scholar 

  7. Poplin E, Levy DE, Berlin J, et al.: Phase III trial of gemcitabine (30-minute infusion) versus gemcitabine (fixed-dose-rate infusion [FDR]) versus gemcitabine + oxaliplatin (GEMOX) in patients with advanced pancreatic cancer (E6201) [abstract]. Proc ASCO 2006, 24:LBA4004.

    Google Scholar 

  8. Phase III study of Avastin in advanced pancreatic cancer does not meet primary endpoint [press release]. South San Francisco, CA: Genentech; June 26, 2006.

  9. Moore MJ, Hamm J, Dancey J, et al.: Comparison of gemcitabine versus the matrix metalloproteinase inhibitor BAY 12-9566 in patients with advanced or metastatic adenocarcinoma of the pancreas: A phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 2003, 21:3296–3302.

    PubMed  Article  CAS  Google Scholar 

  10. Bramhall SR, Rosemurgy A, Brown PD, et al.: Marimastat as first-line therapy for patients with unresectable pancreatic cancer: a randomized trial. J Clin Oncol 2001, 19:3447–3455.

    PubMed  CAS  Google Scholar 

  11. Cheverton P, Friess H, Andras C, et al.: Phase III results of exatecan (DX-8951f) versus gemcitabine (Gem) in chemotherapy-naïve patients with advanced pancreatic cancer (APC) [abstract]. Proc ASCO 2004, 23:314s.

    Google Scholar 

  12. Berlin JD, Catalano P, Thomas JP, et al.: Phase III study of gemcitabine in combination with fluorouracil versus gemcitabine alone in patients with advanced pancreatic carcinoma: Eastern Cooperative Oncology Group Trial E2297. J Clin Oncol 2002, 20:3270–3275.

    PubMed  Article  CAS  Google Scholar 

  13. Riess H, Helm A, Niedergethmann M, et al.: A randomised, prospective, multicenter, phase III trial of gemcitabine, 5-fluorouracil (5-FU), folinic acid vs. gemcitabine alone in patients with advanced pancreatic cancer [abstract]. Proc ASCO 2005, 23:310s.

    Google Scholar 

  14. Herrmann R, Bodoky G, Ruhstaller T, et al.: Gemcitabine (G) plus Capecitabine (C) versus G alone in locally advanced or metastatic pancreatic cancer. A randomized phase III study of the Swiss Group for Clinical Cancer Research (SAKK) and the Central European Cooperative Oncology Group (CECOG). Proc ASCO 2005, 23(16S):310s.

    Google Scholar 

  15. Oettle H, Richards D, Ramanathan RK, et al.: A phase III trial of pemetrexed plus gemcitabine versus gemcitabine in patients with unresectable or metastatic pancreatic cancer. Ann Oncol 2005, 16:1639–1645.

    PubMed  Article  CAS  Google Scholar 

  16. Rocha Lima CM, Green MR, Rotche R, et al.: Irinotecan plus gemcitabine results in no survival advantage compared with gemcitabine monotherapy in patients with locally advanced or metastatic pancreatic cancer despite increased tumor response rate. J Clin Oncol 2004, 22:3776–3783.

    PubMed  Article  CAS  Google Scholar 

  17. Abou-Alfa GK, Letourneau R, Harker G, et al.: Randomized phase III study of exatecan and gemcitabine compared with gemcitabine alone in untreated advanced pancreatic cancer. J Clin Oncol 2006, 24:4441–4447.

    PubMed  Article  CAS  Google Scholar 

  18. Heinemann V, Quietzsch D, Gieseler F, et al.: Randomized phase III trial of gemcitabine plus cisplatin compared with gemcitabine alone in advanced pancreatic cancer. J Clin Oncol 2006, 24:3946–3952.

    PubMed  Article  CAS  Google Scholar 

  19. Louvet C, Labianca R, Hammel P, et al.: Gemcitabine in combination with oxaliplatin compared with gemcitabine alone in locally advanced or metastatic pancreatic cancer: results of a GERCOR and GISCAD phase III trial. J Clin Oncol 2005, 23:3509–3516.

    PubMed  Article  CAS  Google Scholar 

  20. Tobita K, Kijima H, Dowaki S, et al.: Epidermal growth factor receptor expression in human pancreatic cancer: Significance for liver metastasis. Int J Mol Med 2003, 11:305–309.

    PubMed  CAS  Google Scholar 

  21. Durkin AJ, Osborne DA, Yeatman TJ, et al.: EGF receptor antagonism improves survival in a murine model of pancreatic adenocarcinoma. J Surg Res 2006, 135:195–201.

    PubMed  Article  CAS  Google Scholar 

  22. Dragovich T, Hubermann M, von Hoff DD, et al.: Erlotinib plus gemcitabine in patients with unresectable pancreatic cancer and other solid tumors: phase IB trial. Cancer Chemother Pharmacol 2006 (Epub ahead of print)

  23. Kwak EL, Jankowski J, Thayer SP, et al.: Epidermal growth factor receptor kinase domain mutations in esophageal and pancreatic adenocarcinomas. Clin Cancer Res 2006, 12:4283–4287.

    PubMed  Article  CAS  Google Scholar 

  24. Immervol H, Hoem D, Kugarajh K, et al.: Molecular analysis of the EGFR-RAS-RAF pathway in pancreatic ductal adenocarcinomas: lack of mutations in the BRAF and EGFR genes. Virchows Arch 2006, 448:788–796.

    Article  CAS  Google Scholar 

  25. Grubbs SS, Grusenmeyer PS, Petrelli NJ, et al.: Is it cost-effective to add erlotinib to gemcitabine in advanced pancreatic cancer [abstract]? Proc ASCO 2006, 24:313s.

    Google Scholar 

  26. Abbruzzese JL, Grunewald R, Weeks EA, et al.: A phase I clinical, plasma, and cellular pharmacology study of gemcitabine. J Clin Oncol 1991, 9:491–498.

    PubMed  CAS  Google Scholar 

  27. Tempero M, Plunkett W, Ruiz V, et al.: Randomized phase II comparison of dose-intense gemcitabine: Thirty-minute infusion and fixed dose rate infusion in patients with pancreatic adenocarcinoma. J Clin Oncol 2003, 21:3402–3408.

    PubMed  Article  CAS  Google Scholar 

  28. Seo Y, Baba H, Fukuda T, et al.: High expression of vascular endothelial growth factor is associated with liver metastasis and a poor prognosis for patients with ductal pancreatic adenocarcinoma. Cancer 2000, 88:2239–2245.

    PubMed  Article  CAS  Google Scholar 

  29. Solorzano CC, Baker CH, Bruns CJ, et al.: Inhibition of growth and metastasis of human pancreatic cancer growing in nude mice by PTK 787/ZK222584, an inhibitor of the vascular endothelial growth factor receptor tyrosine kinases. Cancer Biother Radiopharm 2001, 16:359–370.

    PubMed  Article  CAS  Google Scholar 

  30. Bruns CJ, Shrader M, Harbison MT, et al.: Effect of the vascular endothelial growth factor receptor-2 antibody DC101 plus gemcitabine on growth, metastasis and angiogenesis of human pancreatic cancer growing orthotopically in nude mice. Int J Cancer 2002, 102:101–108.

    PubMed  Article  CAS  Google Scholar 

  31. Kindler HL, Friberg G, Singh DA, et al.: Phase II trial of bevacizumab plus gemcitabine in patients with advanced pancreatic cancer. J Clin Oncol 2005, 23:8033–8040.

    PubMed  Article  CAS  Google Scholar 

  32. Kindler HL: Clinical trials broadcast: CALGB 80303, A randomized phase III trial of gemcitabine plus bevacizumab versus gemcitabine plus placebo in patients with advanced pancreatic cancer. Clin Adv Hematol Oncol 2005, 3:420–422.

    PubMed  Google Scholar 

  33. Xiong HQ, Rosenberg A, LoBuglio A, et al.: Cetuximab, a monoclonal antibody targeting the epidermal growth factor receptor, in combination with gemcitabine for advanced pancreatic cancer: A multi-center phase II trial. J Clin Oncol 2004, 22:2610–2616.

    PubMed  Article  CAS  Google Scholar 

  34. Tonra JR, Deevi DS, Corcoran E, et al.: Synergistic antitumor effects of combined epidermal growth factor receptor and vascular endothelial growth factor receptor-2 targeted therapy. Clin Cancer Res 2006, 12:2197–2207.

    PubMed  Article  CAS  Google Scholar 

  35. Kindler HL, Bylow KA, Hochster H, et al.: A randomized phase II study of bevacizumab and gemcitabine plus cetuximab or erlotinib in patients with advanced pancreatic cancer: A preliminary analysis [abstract]. Proc ASCO 2006, 24:188s.

    Google Scholar 

Download references

Author information

Affiliations

  1. Section of Hematology/Oncology, University of Chicago, 5841 S. Maryland Avenue, MC 2115, Chicago, IL, IL 60637-1470, USA

    Hedy Lee Kindler MD

Authors
  1. Hedy Lee Kindler MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Kathryn Bylow MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Hedy Lee Kindler MD.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Kindler, H.L., Bylow, K. Pancreatic cancer: An update. Curr Oncol Rep 9, 170–176 (2007). https://doi.org/10.1007/s11912-007-0018-z

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11912-007-0018-z

Keywords

  • Pancreatic Cancer
  • Bevacizumab
  • Gemcitabine
  • Clin Oncol
  • Oxaliplatin